For many women with bipolar disorder, lamotrigine (Lamictal) is an effective mood stabilizer. Given its favorable reproductive safety profile, lamotrigine is a reasonable option for women who require treatment with a mood stabilizer during pregnancy. [...]
Polycystic Ovarian Syndrome (PCOS) is the most common endocrine-related dysfunction in women of reproductive age. Multiple studies have observed a higher prevalence of psychiatric illness, including depressive disorders, anxiety disorders, and bipolar disorder in [...]
Postpartum psychosis (PPP) is a rare but serious psychiatric illness, occurring in 1 to 2 per 1000 women in the weeks. Because postpartum psychosis is so rare, we do not have specific guidelines regarding [...]
Because postpartum psychosis is a relatively rare event, we do not have as much information on this illness as we have on postpartum depression. In addition, most of the literature we have on postpartum psychosis [...]
While the use of lithium has been in decline over the last 20 years, lithium continues to be a useful and highly effective mood stabilizer for women with bipolar disorder. We have long been aware [...]
May 1, 2019 from ObGynNews Publish date: May 1, 2019 By Lee S. Cohen, MD Careful management of bipolar disorder during pregnancy is critical because for so many patients with this illness, the road to emotional [...]
We don’t hear this clinical question so often but it does come up from time to time. While the anticonvulsant oxcarbazepine (Trileptal) was initially promoted as a mood stabilizer for patients with bipolar disorder, it [...]
We have long known that postpartum depression may have negative effects on the child and may contribute to deficits in social development and emotional regulation. Exactly what mediates these effects is not so clear; however, [...]
Last year France banned the use of the antiepileptic during valproate in certain populations of reproductive age women. Now the United Kingdom's Medicines and Healthcare products Regulatory Agency (MHRA) has banned the use of [...]
The use of the newer “atypical” or second-generation antipsychotic (SGA) agents continues to increase. These medications are used to treat a spectrum of psychiatric disorders, including schizophrenia, bipolar disorder, major depression, PTSD and anxiety disorders. [...]